2012 Korea Outlook: More Tough Times Seen For Pharma As Grip Tightens On Irregular Business Deals and Price Cuts

By Peter Chang / Email the Author / PharmAsia News Dec. 16, 2011 4:00 PM GMT
Korea / Word Count: 1834 / Article # 28111215001

Executive Summary

A crack down on rebates and new price cuts will force Korean pharma companies to shift focus to R&D in 2012 and seek out more co-promotion deals with Big Pharma.

Purchase this Article

$85.00 Buy Now

For $85.00, purchase this 1834-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: 2012 Korea Outlook: More Tough Times Seen For Pharma As Grip Tightens On Irregular Business Deals and Price Cuts

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to PharmAsia News will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

2012 Korea Outlook: More Tough Times Seen For Pharma As Grip Tightens On Irregular Business Deals and Price Cuts

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 22

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article